- testing |
| Purpose | Board Meetings Date | Announcement Date |
|---|---|---|
| Board Meeting | 26 May 2025 | 19 May 2025 |
| Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Monday, 26 May 2025 inter alia to consider and approve the following: (a) audited financial statements (Consolidated & Standalone) for the financial year ending March 31, 2025 (b) audited financial results (Consolidated & Standalone) for the quarter and financial year ending March 31, 2025, pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. (c ) recommendation of dividend, if any for the Financial Year 2024-25. BM outcome (As Per BSE Announcement Dated on: 26/05/2025) | ||
| Board Meeting | 10 Feb 2025 | 3 Feb 2025 |
| SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/02/2025 inter alia to consider and approve The Meeting of Board of Directors of the Company will be held on Monday 10 February 2025 to inter alia consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December 2024. In terms of the Code of Conduct for Prevention of Insider Trading in Securities of the Company the Trading Window has been closed with effect from 1 January 2025 and remains closed upto 48 hours after the declaration of Un-Audited Standalone and Consolidated Financial Results of the Company for the quarter and nine-months ended 31 December 2024 BM outcome Integrated filing (As Per BSE Announcement Dated on 10/02/2025) | ||
| Board Meeting | 13 Nov 2024 | 4 Nov 2024 |
| SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2024 inter alia to consider and approve Consider The Un-Audited Standalone And Consolidated Financial Results For The Quarter Ended 30 September 2024 Considered and approved 1.The Un-Audited Financial Results (Standalone and Consolidated) for the quarter and half year ended 30 September 2024. A copy of Un-Audited Financial Result along with the Limited Review report is enclosed as Annexure 1. 2.Inducted Dr. Anita Bandyopadhyay, Non-Executive Independent Director as a member of Audit Committee. (As Per BSE Announcement dated on 13.11.2024) | ||
| Board Meeting | 8 Aug 2024 | 31 Jul 2024 |
| SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 08/08/2024 inter alia to consider and approve Intimation of Board Meeting to consider the Un-Audited Standalone and Consolidated Financial Results for the quarter ended 30 June 2024 Unaudited financial results for the quarter ended 30th June, 2024 Revised outcome of the Board meeting held on 08 August 2024 Outcome of Board Meeting (As per BSE Announcement Dated on 08/08/2024) | ||
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.